ALTEPLASE
Background and Date of Approval
Alteplase, marketed as Activase, was approved by the FDA on November 10, 1987, for the treatment of acute myocardial infarction.
Uses
Alteplase is used to dissolve blood clots and restore blood flow in conditions such as acute ischemic stroke, acute myocardial infarction (heart attack), and pulmonary embolism.
How is it administered?
Alteplase is administered intravenously (injection in a vein) under medical supervision. Your healthcare professional will determine the specific dosage and administration guidelines based on your condition and needs.
Side Effects
Alteplase may cause several side effects, the most significant being an increased risk of bleeding, which can lead to serious and life-threatening complications. Other common side effects include fever, headache, nausea, vomiting, and bleeding at the injection site. Serious allergic reactions and hypersensitivity may occur in some individuals.
Warnings
Alteplase carries several warnings that should be considered before use. Serious allergic reactions, including anaphylaxis, can necessitate immediate medical attention if symptoms like difficulty breathing or facial swelling occur. This medication significantly increases the risk of bleeding. Serious bleeding events can occur at various sites in the body, including the brain, gastrointestinal tract, and other critical locations. It can lead to bleeding in the brain, resulting in a condition called intracranial hemorrhage. This is a severe and potentially life-threatening complication. In some cases, blood vessels may re-occlude (re-form blood clots) after initial treatment. This may necessitate additional interventions to address the recurrent clotting. It can cause a drop in blood pressure (hypotension), leading to symptoms such as dizziness, lightheadedness, or fainting.
Precautions
It is essential to avoid using alteplase in patients with active bleeding or a history of recent significant bleeding events. Due to the risk, this medication is contraindicated in patients with a history of intracranial hemorrhage or known structural cerebral vascular lesions. Close monitoring of blood pressure is crucial during treatment.
Word of Advice
Before starting Alteplase or modifying your medication regimen, consult your healthcare provider. Inform your doctor of any history of bleeding disorders, recent surgery or trauma, gastrointestinal bleeding, or other conditions that may elevate bleeding risk. Patients require close monitoring throughout treatment to identify any bleeding or adverse reactions without delay. This medication must be administered in a hospital setting with access to emergency facilities, and immediate medical care must be available should complications occur. Patients who are pregnant or breastfeeding should consult their doctor before starting treatment. Advanced age increases the risk of bleeding complications with this medication, particularly in patients over 75 years. Dosage adjustment is necessary in elderly patients.
References
KD Tripathi, Essentials of Medical Pharmacology, Drugs affecting coagulation, bleeding and thrombosis, 7th edition, 2013, 627. Boehringer Ingelheim International GmbH, European medicines compendium (emc), [Revised on April 2021] [ Accessed on 24th March 2023], https://www.medicines.org.uk/emc/files/pil.10361.pdf Genentech, Inc, US Food and Drug Administration, [Revised on August 2001] [Accessed on 24th Jult 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/altegen090401lb.pdf
Frequently Asked Questions
Is alteplase effective in all cases of stroke or blood clots?
Alteplase is most effective when administered within the recommended time window and in specific cases of acute ischemic stroke, pulmonary embolism, or myocardial infarction. Its use must be carefully evaluated on a case-by-case basis by qualified healthcare professionals.
Are there any contraindications for using alteplase?
Alteplase is contraindicated in certain conditions, such as active bleeding, recent major surgery, intracranial hemorrhage, known hypersensitivity to it, and other situations with an increased risk of bleeding.
Are there any specific tests required before administering alteplase?
Before administering alteplase, healthcare professionals typically perform brain imaging (CT or MRI) to rule out hemorrhagic stroke, a contraindication for this medication use. They may also conduct blood tests to assess coagulation parameters and ensure that the patient meets the necessary criteria for treatment.
Is there a reversal agent for alteplase if bleeding occurs?
There is no specific reversal agent for alteplase. In case of severe bleeding complications, healthcare professionals may use supportive measures, blood products, or other interventions to manage bleeding. Close monitoring and immediate medical attention are essential to address any adverse events promptly.
Can alteplase be used in children or adolescents?
Alteplase is not approved for use in children or adolescents for stroke treatment. Its use in this population is limited to specific cases and requires expert evaluation and consideration of the risks and benefits.